atherosclerosis, cardiovascular disease, primary prevention, intermediate risk patients, normal or high cholesterol
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2016 May 26;374(21):2021-31 Randomized Controlled Trial, Multicenter Study
IN atherosclerosis, cardiovascular disease, primary prevention, intermediate risk patients, normal or high cholesterol The Use of
statins, rosuvastatin 10 mg/day for > 5 years
As Prevention, Primary
Is better Than
placebo
To reduce cardiovascular events (cardiovascular death, nonfatal myocardial infarction or stroke) at 5.6 years: 3.7% rosuvastatin VS 4.8% placebo. No difference in mortality: 2.8-2.9% both. Muscle symptoms in 5.8% of patients on rosuvastatin.